Researchers at the Karolinska Institute in Stockholm, Sweden, assessed whether early improvements in obstructive sleep apnea after a very low energy diet were maintained one year later in 63 men, aged 30 to 65 years, with moderate to severe obstructive sleep apnea and body mass index of 30 to 40 kg/m². Participants were treated with continuous positive airway pressure and underwent a one-year weight loss program consisting of nine weeks of a very low energy diet followed by a weight loss maintenance program, which was completed by 44 men. The severity of sleep apnea was measured using the apnea hypopnea index. Read the rest of this entry
Women with obstructive sleep apnea (OSA) and cardiac symptoms have a 31 percent incidence of cardiac dysfunction. Researchers have recommended use of echocardiograms should be considered in the clinical management of these women.
Obstructive sleep apnea (OSA) is characterized by abnormal pauses in breathing or instances of abnormally low breathing, during sleep. These pauses can last from at least ten seconds to minutes, and may occur five to 30 times or more an hour; this can lead to cardiovascular disease.
Researchers conducted an observational study with an objective to measure the incidence of OSA among pregnant and reproductive women. Read the rest of this entry
A research concluded recently has revealed its findings that those who are suffering from obstructive sleep apnea (OSA) may control the sleep issue while traveling to higher altitudes if they can combine auto-adjusted continuous positive airway pressure (autoCPAP) with acetazolamide.
“Our study provides important information for patients with OSA planning a stay at altitude because they can continue using their CPAP in auto-adjusting mode during altitude travel and enhance this treatment with acetazolamide if they want to spend less time awake at night, to achieve a higher arterial oxygen saturation and an optimal control of sleep apnea,” said Konrad Bloch, from University Hospital of Zurich in Switzerland. Read the rest of this entry
Researchers accomplished a detailed investigation whether OSA is associated with increased cancer incidence in a large clinical cohort.
Multicenter, clinical cohort study including consecutive patients investigated for suspected OSA between 2003-2007 in 7 Spanish teaching hospitals. Apnea-hypopnea index (AHI) and percent night-time with oxygen saturation <90% (TSat90) were used as surrogates of OSA severity, both as continuous variables and categorized by tertiles. Cox proportional hazards regression analyses were used to calculate hazard ratios (HR) and 95%CI for cancer incidence after adjusting for confounding variables. Read the rest of this entry
A study appearing in the November 2011 issue of the Journal of Clinical Sleep Medicine finds that obstructive sleep apnea (OSA) patients treated with Provent Sleep Apnea Therapywere not only compliant with the therapy but also showed a reduction in apnea-hypopnea index (AHI).
“This study provides further validation that Provent Therapy is an effective treatment for some OSA patients as it reduces daytime sleepiness, apnea-hypopnea index (AHI), and snoring associated with this prevalent condition,” said Meir Kryger, MD, of Gaylord Sleep Medicine and past president of the American Academy of Sleep Medicine.
“Patients reported wearing the device almost 90% of the nights, which represents very high compliance. The current gold standard, continuous positive airway pressure (CPAP) is very effective but many patients do not use it adequately. Provent represents an important new treatment option for many obstructive sleep apnea patients.” Read the rest of this entry
Ventus Medical revealed the results of a large, long-term study of its proprietary Provent® Sleep Apnea Therapy, an innovative, non-invasive treatment for obstructive sleep apnea (OSA), were published in the November 2011 issue of the Journal of Clinical Sleep Medicine, an official publication of the American Academy of Sleep Medicine.
Obstructive sleep apnea (OSA) is a common yet underdiagnosed condition. The aim of our study is to test whether prediabetes and type 2 diabetes are associated with obstructive sleep apnea (OSA) in extremely obese (BMI [greater than or equal to] 40 kg/m2) subjects.
One hundred and thirty seven consecutive extremely obese patients (99 females) from a controlled clinical trial [MOBIL-study (Morbid Obesity treatment, Bariatric surgery versus Intensive Lifestyle intervention Study) (ClinicalTrials.gov number NCT00273104)] underwent somnography with Embletta(R) and a 2-hour oral glucose tolerance test (OGTT). Read the rest of this entry
Transcend, the new wearable sleep apnea therapy device designed by Somnetics International Inc. to be the ultimate travel CPAP, now measures apnea-hypopnea index (AHI). While AHI measurement is not new to CPAPs, it is a new standard feature on Transcend thereby giving users added value at no additional cost.
Used to assess the severity of a patient’s sleep apnea, AHI is a numerical measure that accounts for the number of pauses in breathing per hour of sleep. Leak detection helps assess the appropriateness of the mask used by the patient. In measuring AHI and leak detection, Transcend also helps assess the efficacy of the patient’s pressure setting. Valuable to both patients and doctors, this information can be used to identify issues with the therapy and to determine how changes to the system setup affects overall treatment. Read the rest of this entry
Women with severe sleep apnea have the highest incidence of adverse pregnancy outcomes. This increased prevalence was primarily driven by a higher incidence of gestational diabetes and early preterm birth.
“Our findings suggest that moderate to severe sleep-disordered breathing may be associated with adverse pregnancy outcomes, particularly gestational diabetes and preterm birth,” principal investigator Dr. Francesca L. Facco, assistant professor in the department of obstetrics and gynecology at Northwestern University in Chicago, was quoted as saying.
“However, it is unclear if sleep-disordered breathing is a risk factor for adverse pregnancy outcomes independent of obesity.” Read the rest of this entry
New research that will be presented Saturday, June 11, at the 20th Anniversary Meeting of the American Academy of Dental Sleep Medicine (AADSM) in Minneapolis, Minn., quantified the efficacy of mandibular advancement splints (MAS) using a self-administered, at-home device to monitor snoring and sleep-disordered breathing. Clinical assessment of MAS efficacy in the treatment of snoring and obstructive sleep apnea (OSA) is based predominantly on subjective reports by the patient and partner, and less commonly, on the apnea hypopnea index (AHI), which is the average number of pauses in breathing that occur per hour of sleep. The current study used the Sonomat, a portable, unobtrusive device that has sensors contained within a mattress overlay. These sensors measure AHI by detecting and recording snoring, breathing and body movements.
Results show that MAS treatment reduced the average AHI from 10.3 events per hour to 3.8 events per hour. The respiratory event movement index (RMI), which records more types of events than AHI, was reduced from 15.9 events per hour to 7.6 events per hour. Read the rest of this entry